company background image
NB3 logo

Neurocrine Biosciences DB:NB3 Stock Report

Last Price

€128.75

Market Cap

€12.9b

7D

0.7%

1Y

44.3%

Updated

26 Mar, 2024

Data

Company Financials +

Neurocrine Biosciences, Inc.

DB:NB3 Stock Report

Market Cap: €12.9b

NB3 Stock Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.

NB3 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Neurocrine Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Neurocrine Biosciences
Historical stock prices
Current Share PriceUS$128.75
52 Week HighUS$135.35
52 Week LowUS$83.18
Beta0.24
1 Month Change4.97%
3 Month Change9.06%
1 Year Change44.31%
3 Year Change49.71%
5 Year Change64.52%
Change since IPO322.13%

Recent News & Updates

Recent updates

Shareholder Returns

NB3DE BiotechsDE Market
7D0.7%3.3%1.6%
1Y44.3%35.8%6.4%

Return vs Industry: NB3 exceeded the German Biotechs industry which returned 35.8% over the past year.

Return vs Market: NB3 exceeded the German Market which returned 6.4% over the past year.

Price Volatility

Is NB3's price volatile compared to industry and market?
NB3 volatility
NB3 Average Weekly Movement4.1%
Biotechs Industry Average Movement5.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: NB3 has not had significant price volatility in the past 3 months.

Volatility Over Time: NB3's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19921,400Kevin Gormanhttps://www.neurocrine.com

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications.

Neurocrine Biosciences, Inc. Fundamentals Summary

How do Neurocrine Biosciences's earnings and revenue compare to its market cap?
NB3 fundamental statistics
Market cap€12.89b
Earnings (TTM)€230.55m
Revenue (TTM)€1.74b

56.3x

P/E Ratio

7.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NB3 income statement (TTM)
RevenueUS$1.89b
Cost of RevenueUS$604.70m
Gross ProfitUS$1.28b
Other ExpensesUS$1.03b
EarningsUS$249.70m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)2.51
Gross Margin67.96%
Net Profit Margin13.23%
Debt/Equity Ratio7.6%

How did NB3 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.